Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females

Next Previous
Trial Profile

BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Major depressive disorder
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Allergan

Most Recent Events

  • 11 Oct 2019 Results assessing the efficacy, safety, and duration of effect of a single-treatment session of onabotA compared to placebo for the treatment of major depressive disorder in adult females published in the International Clinical Psychopharmacology
  • 05 Apr 2017 Primary endpoint of change from baseline in the clinic 10-item montgomery-asberg depression rating scale (MADRS) total score for Botulinum toxin A 30 U vs. placebo has been met, according to results published in an Allergan media release.
  • 05 Apr 2017 Top-line results published in an Allergan media release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top